Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker

Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01198808

Enrollment

Registered

2010-09-10

Start date

2010-08-31

Completion date

Unknown

Last updated

2012-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Bladder cancer, chemotherapy, T cells, Immunotherapy, Tumor-specific immunity in bladder cancer

Brief summary

Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy. It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Histologically confirmed muscle-invasive urothelial carcinoma * Age \> 18 years * Hemoglobin \> 10g/dl * Signed Informed Consent * Karnofsky index \< 70%

Exclusion criteria

* Clinically relevant second malignancy * Severe comorbidities (e.g. NYHA III, end-stage renal disease) * Chronic infectious disease (HIV, Tuberculosis) * Immunosupression * Severe psychiatric diseases * Blood donation in the last 4 weeks

Countries

Germany

Outcome results